Page 6,798«..1020..6,7976,7986,7996,800..6,8106,820..»

Biostem U.S., Corporation Engages Acropolis Agency to Assist in Implementing Its International Marketing Plan

Posted: Published on June 8th, 2012

CLEARWATER, FL--(Marketwire -06/08/12)- Biostem U.S., Corporation, (HAIR) (HAIR) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, today reported that it has engaged Acropolis Inc. http://www.acropolisinc.com, a full-service advertising agency located in Orlando, Florida, to lend their expertise in brand building, marketing, and advertising development and placement. Biostem Chief Executive Officer Dwight Brunoehler stated, "After several months of interviewing prospective agencies, we have come to the conclusion that Acropolis is the one to assist us in executing our plans. Their notable work in multiple media areas is impressive, to say the least. Their client list including The University of Florida, Arby's Restaurants, and the City of Orlando, speaks for itself." Acropolis Principal, Scott Major, said, "This is a great fit for Acropolis. Our entire team loves the Biostem business approach in the incredible field of regenerative medicine. The hair re-growth field in which we will be marketing the Biostem technology is enormous. We are pleased to be a part of Biostem's expansion." About Biostem U.S. CorporationBiostem U.S., Corporation is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered on providing hair re-growth … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Biostem U.S., Corporation Engages Acropolis Agency to Assist in Implementing Its International Marketing Plan

OMICS Group :: Journal of Stem Cell Research

Posted: Published on June 8th, 2012

07-06-2012 07:52 Stem cells differ from other types of cells as they are unspecialized cells that are capable of differentiating into almost any type of specialised cells. Stem cells have the ability to replace the diseased and damaged tissue in the body, without the risk of rejection and any side effects. Therapy performed using stem cells is termed as "Regenerative medicine" and has many potential benefits in treating a wide variety of diseases and injuries. The journal is the major open access forum for translational research in stem cell therapies. Read the original here: OMICS Group :: Journal of Stem Cell Research … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on OMICS Group :: Journal of Stem Cell Research

TiGenix: National Reimbursement in the Netherlands Obtained for Breakthrough Cartilage Therapy ChondroCelect(R)

Posted: Published on June 8th, 2012

LEUVEN, BELGIUM--(Marketwire -06/08/12)- TiGenix (EURONEXT:TIG) TiGenix obtains national reimbursement in the Netherlands for breakthrough cartilage therapy ChondroCelect TiGenix (EURONEXT:TIG) announced today that its innovative cartilage repair therapy ChondroCelect has obtained national reimbursement in the Netherlands. The Dutch National Health Authority (NZa) has formally announced that ChondroCelect is to receive national reimbursement retroactively per January 1, 2012. Previously ChondroCelect was made available in the Netherlands under a risk-sharing scheme. "We are delighted with the decision of the NZa to reimburse ChondroCelect, and look forward to working with Dutch orthopedic centers of excellence and health insurers to routinely make this breakthrough therapy available to the right patients in the Netherlands," said Eduardo Bravo, CEO of TiGenix. "Dutch clinicians and scientists have been instrumental in ChondroCelect's development and four Cartilage Expert Centers in the Netherlands have already gained extensive experience with the procedure. After having obtained national reimbursement in Belgium last year, this constitutes another major step in improving patient access to this innovative therapy. We remain optimistic that we can obtain national reimbursement in other European countries later this year." About TiGenix TiGenix NV (EURONEXT:TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect, and a … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on TiGenix: National Reimbursement in the Netherlands Obtained for Breakthrough Cartilage Therapy ChondroCelect(R)

Big Brother Ashleigh talks golden showers, penis enlargement

Posted: Published on June 8th, 2012

Essex's Ashleigh Hughes brought up the subjects of golden showers and penis enlargement during the opening night in the Big Brother house. Ashleigh, 20, admitted to her co-stars that she would consider urinating on a lover if she had been in a relationship for over four years and things needed "spicing up". Rex Features / David Fisher Speaking to Arron Lowe and Shievonne Robinson, Ashleigh said: "Has anyone done water sports? That is the question!" Arron said: "As in..." Ashleigh replied: "I mean p*ssing on people's faces. "If I'd been in a four-year-relationship and someone said, 'Let's spice up the relationship'. Because you're in that four-year zone... I'd do it." > Big Brother's Lydia upset over Shievonne "fame" joke Opening up the topic to the rest of the group, she added: "P*ssing on people's faces. Who does it? "Every boy has got that fantasy. Every boy has got a fantasy of p*ssing on a girl." See the original post: Big Brother Ashleigh talks golden showers, penis enlargement … Continue reading →

Posted in Penis Enlargement | Comments Off on Big Brother Ashleigh talks golden showers, penis enlargement

Newton: 'Sliced Bread' getting a little stale?

Posted: Published on June 8th, 2012

CHARLOTTE, N.C. -- Joey Logano was on a bar stool in the Daytona 500 Club before a January test session, but he might as well have been on a witness stand in a courtroom the way he was being pounded with questions about how this is a make-or-break season, how if he doesn't make the Chase, his future with Joe Gibbs Racing is in jeopardy. "Obviously, this is a contract year," Logano responded calmly. "Obviously, I see where you're coming from. [I] better pick it up. I understand that. I see that." Judging by the weekly questions on ESPN.com chats, the daily emails and comments on Twitter, many don't believe Logano has done that. Many believe he's got a foot out the door even though team owner Joe Gibbs has shown nothing but confidence in his 22-year-old driver in only his fourth year in the Sprint Cup Series. John David Mercer/US PresswireJoey Logano sits 16th in the Cup standings, but he's got four wins this season in the Nationwide Series. Some have speculated that Kurt Busch already has been penciled in as the next driver for the No. 20 Home Depot car. Well, they did before Busch's meltdown with yet … Continue reading →

Posted in Premature Ejaculation | Comments Off on Newton: 'Sliced Bread' getting a little stale?

Bio-Matrix Scientific Group’s Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual …

Posted: Published on June 8th, 2012

SAN DIEGO, CA--(Marketwire -06/07/12)- Bio-Matrix Scientific Group, Inc. (BMSN) (BMSN) announced today that its wholly owned subsidiary Regen BioPharma, Inc. has executed an exclusive option agreement which grants Regen BioPharma an option to license Patent #6,821,513 which patents methods of stimulating blood production in patients with deficient stem cells. The patent, as well as data licensed with the patent, covers methods of stimulating the bone marrow to generate new blood cells. The patent and option agreement are disclosed in the Company's most recent 8K filed with the US Securities and Exchange Commission on June 6, 2012. "The technology has broad applicability to help cancer patients recover faster following chemotherapy, as well as for recipients of bone marrow and cord blood transplants. Currently, new blood cell production is stimulated by expensive drugs such as Neupogen and Neulasta which replicate the body's growth factors but can cause side effects and rely upon the diminished recuperative powers of an immune compromised patient," stated J. Christopher Mizer, President of Regen BioPharma. David Koos, Chairman & CEO of Bio-Matrix Scientific Group, added, "We are excited to get this therapy into the clinic. Based on peer-reviewed published animal data, it has the potential to restore immune … Continue reading →

Posted in Cell Medicine | Comments Off on Bio-Matrix Scientific Group’s Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual …

Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual …

Posted: Published on June 8th, 2012

SAN DIEGO, CA--(Marketwire -06/07/12)- Bio-Matrix Scientific Group, Inc. (BMSN) (BMSN) announced today that its wholly owned subsidiary Regen BioPharma, Inc. has executed an exclusive option agreement which grants Regen BioPharma an option to license Patent #6,821,513 which patents methods of stimulating blood production in patients with deficient stem cells. The patent, as well as data licensed with the patent, covers methods of stimulating the bone marrow to generate new blood cells. The patent and option agreement are disclosed in the Company's most recent 8K filed with the US Securities and Exchange Commission on June 6, 2012. "The technology has broad applicability to help cancer patients recover faster following chemotherapy, as well as for recipients of bone marrow and cord blood transplants. Currently, new blood cell production is stimulated by expensive drugs such as Neupogen and Neulasta which replicate the body's growth factors but can cause side effects and rely upon the diminished recuperative powers of an immune compromised patient," stated J. Christopher Mizer, President of Regen BioPharma. David Koos, Chairman & CEO of Bio-Matrix Scientific Group, added, "We are excited to get this therapy into the clinic. Based on peer-reviewed published animal data, it has the potential to restore immune … Continue reading →

Posted in Cell Medicine | Comments Off on Bio-Matrix Scientific Group's Regen BioPharma Subsidiary Executes Option Agreement to License Stem Cell Intellectual …

Curis Announces Publication of Erivedge(TM) Data in the New England Journal of Medicine

Posted: Published on June 8th, 2012

LEXINGTON, Mass., June 7, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that two publications describing clinical data generated with Erivedge(TM) (vismodegib, GDC-0449) capsule were published in the current edition of The New England Journal of Medicine (NEJM). The first publication, entitled "Efficacy and Safety of Vismodegib in Advanced Basal Cell Carcinoma," reports on the results of the pivotal Phase II ERIVANCE BCC study in 104 patients with advanced basal cell carcinoma (BCC) conducted by Genentech. The second publication, entitled "Inhibiting the Hedgehog Pathway in Patients with Basal-Cell Nevus Syndrome," reports on results from an investigator-sponsored study evaluating the potential of Erivedge in 41 patients with basal cell nevus syndrome (BCNS) and surgically eligible BCCs. Erivedge is a first-in-class oral medicine designed to selectively inhibit signaling in the Hedgehog pathway. It is also is the only FDA-approved medicine for patients with advanced BCC. There are currently no approved medicines for advanced BCC outside the United States. Erivedge is being developed by Roche and Genentech, under a collaboration agreement between Curis and Genentech, a member of the Roche Group. "The published ERIVANCE BCC … Continue reading →

Posted in Cell Medicine | Comments Off on Curis Announces Publication of Erivedge(TM) Data in the New England Journal of Medicine

Neil Riordan PhD – Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments – Video

Posted: Published on June 8th, 2012

06-06-2012 13:09 Mesenchymal stem cell homing to tissue damage, umbilical cord stem cells historically used for anti-aging, mesenchymal stem cells role in immune system modulation, inflammation reduction and stimulating tissue regeneration, donor stem cell safety and testing, the role of HLA matching in donated umbilical cord-derived stem cells, umbilical cord blood safety data and historical use in blood transfusions, allogeneic stem cell persistence in human mothers. Treatment information at More information on Dr. Riordan at Continue reading here: Neil Riordan PhD - Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments - Video … Continue reading →

Posted in Cell Therapy | Comments Off on Neil Riordan PhD – Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments – Video

Neil Riordan PhD – Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments – Video

Posted: Published on June 8th, 2012

06-06-2012 13:09 Mesenchymal stem cell homing to tissue damage, umbilical cord stem cells historically used for anti-aging, mesenchymal stem cells role in immune system modulation, inflammation reduction and stimulating tissue regeneration, donor stem cell safety and testing, the role of HLA matching in donated umbilical cord-derived stem cells, umbilical cord blood safety data and historical use in blood transfusions, allogeneic stem cell persistence in human mothers. Treatment information at More information on Dr. Riordan at Continue reading here: Neil Riordan PhD - Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments - Video … Continue reading →

Posted in Cell Therapy | Comments Off on Neil Riordan PhD – Stem Cell Therapy for Spinal Cord Injury (Part 3 of 5) || Stem Cell Treatments – Video

Page 6,798«..1020..6,7976,7986,7996,800..6,8106,820..»